Map Home
Type / to search with text or keywords
/
keyboard shortcut: Type "/" on your keyboard for a quick search
Search button
Loading...
Loading...
Scroll left
Grants
Citations
H-Index
Patents
News
Books
Scroll right
Collapse sidebar
Data issues & feedback
Adjust height of sidebar
KMap
Funding Agency
For Profit
(FP)
People
Conrad Clemens
Health Promotion Sciences
Senior Associate Dean
Abhijeet Kumar
Medicine
Associate Professor, Medicine - (Clinical Scholar Track)
Klearchos Papas
Surgery
Professor
Sasha Taleban
Medicine
Associate Professor
Franz Rischard
Medicine
Professor
Kirsten Anderson
Senior VP Health Sciences
Research Compliance Administrator IV
VENKATESH KUMAR ARIYAMUTHU
Medicine
Associate Professor, Medicine - (Clinical Scholar Track)
Rachna Shroff
Medicine
Professor
Cori Daines
Pediatrics
Professor
Elena Young
COM - Phoenix Internal Medicine
Research Compliance Manager II
Recent Grants
A Phase 3, Open-Label Study to Evaluate Safety and Efficacy of Epcoritamab in Combination with Rituximab and Lenalidomide (R2) Compared to R2 in Subjects with Relapsed or Refractory Follicular Lymphom
Active
·
2024
·
$1.2M
A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Efficacy and Safety of Upadacitinib in Adult and Adolescent Subjects with Moderate to Severe Hidradenitis Suppurativa Who Have
Active
·
2024
·
$964K
Study to Evaluate Safety, Efficacy and Tolerability of ABBV-950 for the Treatment of Upper Limb Spasticity in Adult Post-Stroke Patients
Active
·
2024
·
$822.1K
Phase 1 Trial Evaluating the Safety and Tolerability of Gamma Delta T-Cell Infusions in Combination with Low Dose Radiotherapy in Subjects with Stage 4 Metastatic Non-Small Cell Lung Cancer
Active
·
2024
·
$577.4K
A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) Tablets for the Delay of Encephalopathy Decompensation i
Active
·
2024
·
$556.1K
A Randomized, Phase 2, Double-blind, Placebo-controlled Study to Investigate the Safety and Efficacy of KER-012 in Combination with Background Therapy in Adult Participants with Pulmonary Arterial Hyp
Active
·
2024
·
$555.7K
A Phase 1b Study of the OxPhos Inhibitor ME-344 Combined With Bevacizumab in Previously Treated Metastatic Colorectal Cancer
Active
·
2024
·
$502.8K
A Phase 2b, Multinational, Randomized, Double-blind Study to Investigate the Efficacy and Safety of Redasemtide (S-005151) Compared With Placebo in Adult Participants With Acute Ischemic Stroke Who Ar
Active
·
2024
·
$470.3K
Brightline-2: A Phase IIa/IIb, Open-label, Single-arm, Multi-centre Trial of BI 907828 for Treatment of Patients With Locally Advanced / Metastatic, MDM2 Amplified, TP53 Wild-type Biliary Track Adenoc
Active
·
2024
·
$462K
VR/AR Optical Architecture Design Exploration
Active
·
2024
·
$372.7K
773.2M Funding
689 People
1770 Grants